BNTX today
$86.35-$1.30 (-1.48%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourBearish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns up above $124.00
Key levels
Resistance$95.20
Resistance$90.32
Support$84.89
Support$79.52
Latest news & SEC filings
DealBioNTech buys a fast-track review voucher from the FDA
DealBioNTech pays Scholar Rock $205M for faster FDA review pass
AnalystHC Wainwright keeps Buy rating on BioNTech, cuts price target to $110
All BNTX news →About BioNTech
BioNTech is a German immunotherapy company that develops treatments for cancer, infections, and other severe illnesses. Its work spans mRNA-based therapies and protein-based medicines, including antibodies and antibody-drug conjugates. The company's approved product is Comirnaty, a COVID-19 vaccine made with Pfizer, which handles marketing and distribution in most of the world except Germany, Turkey, and Greater China. BioNTech also runs a large pipeline of cancer drug candidates in clinical trials, often alongside other pharmaceutical partners.
Based on the company's 20-F filed Mar 10, 2026.
Nasdaq · Healthcare
BioNTech SE (BNTX)
What Is the Price Target for BNTX?
SEPT Low Target
$96.00
SEPT Mid Target
$130.00
SEPT High Target
$140.00
Analyst Consensus
$130.00
Is BNTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.8% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BNTX.
Start Free Trial →Is BNTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$130.00
27
Moat Score
NONE
4/9
Piotroski Score
5.7
Altman Z-Score
What Is Smart Money Doing with BNTX?
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sahin Ugur | officer 10% owner | Sale | 36,209 | $3.5M | Oct 9, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 27,000 | $2.5M | Oct 8, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 24,000 | $2.3M | Oct 7, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 21,000 | $2.0M | Oct 6, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 72,000 | $7.0M | Oct 5, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 32,000 | $3.1M | Sep 30, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 34,000 | $3.3M | Sep 29, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 34,000 | $3.3M | Sep 28, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 27,000 | $2.7M | Sep 25, 2026 |
| Sahin Ugur | officer 10% owner | Sale | 39,000 | $3.9M | Sep 24, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BNTX Growth Story
Revenue YoY
8.8%
3yr Revenue CAGR
-43.8%
EPS Growth YoY
-77%
FCF Growth YoY
471.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for BNTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BNTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:55:42 | $86.30 | 1,746 | $$151K | SELL |
| 16:14:48 | $86.28 | 1,100 | $$95K | SELL |
| 15:30:16 | $85.11 | 1,000 | $$85K | SELL |
| 15:29:15 | $85.02 | 3,074 | $$261K | SELL |
| 14:54:28 | $86.72 | 1,600 | $$139K | MIDPOINT |
5 dark pool trades shown · $$731K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for BNTX
PREVIEWSEPT Investing provides real-time options flow tracking for BNTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $85 | Nov 20 | 8 | $$275 | 1 | SWEEP |
| CALL | $85 | Nov 20 | 8 | $$1100 | 4 | SWEEP |
| CALL | $85 | Nov 20 | 8 | $$275 | 1 | SWEEP |
| CALL | $85 | Nov 20 | 8 | $$9900 | 36 | SWEEP |
| CALL | $85 | Nov 20 | 8 | $$834 | 3 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About BNTX
5 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for BNTX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$BNTX filed a 6-K on Tue Nov 10: BioNTech SE announced an agreement to acquire a US FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million in cash.
Smart Money Moves $VFF — DEGIGLIO MICHAEL A | Sale $101K $RMCF — KEATING MELVIN L | Sale $GOLD — BENJAMIN JEFFREY D | Sale $363K $GOLD — BENJAMIN JEFFREY D | Sale $440K $BNTX — Sahin Ugur | Sale $4.6...
Smart Money Moves $TOON — THOMOPOULOS ANTHONY D | Sale $TOON — Davis Gray | Sale $TOON — LOESCH MARGARET | Sale $LITE — Wupen Yuen | Sale $460K $BNTX — Sahin Ugur | Sale $2.9M
Join 3,500+ traders discussing BNTX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BioNTech SE (BNTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BNTX — frequently asked questions
What is BNTX stock price today?
BioNTech SE (BNTX) is at $86.35, down 1.48% (-$1.30) at the Nov 12, 2026 close.
Why is BNTX stock moving today?
Latest BNTX news — Nov 10, 2026: BioNTech buys a fast-track review voucher from the FDA · Nov 10, 2026: BioNTech pays Scholar Rock $205M for faster FDA review pass
What is the BNTX price target?
The average analyst price target for BNTX is $130.00, ranging from $96 to $140, based on 11 analysts. Latest: Canaccord Genuity maintains on Oct 14, 2026.
What do analysts rate BNTX?
Analyst ratings for BNTX: 1 Buy, 12 Hold, 1 Sell — consensus Hold.
Did BNTX beat earnings?
BNTX last reported on Nov 3, 2026: EPS $2.03 vs $0.85 expected — a beat of 139.4%.
Does BNTX pay a dividend?
BNTX does not currently pay a dividend.
What are BNTX support and resistance levels?
Support: $84.89, $79.52, $76.53. Resistance: $90.32, $95.20, $100.02.
What are insiders doing with BNTX?
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
What is the latest news on BNTX?
Nov 10, 2026: BioNTech buys a fast-track review voucher from the FDA · Nov 10, 2026: BioNTech pays Scholar Rock $205M for faster FDA review pass · Nov 9, 2026: HC Wainwright keeps Buy rating on BioNTech, cuts price target to $110